Case Report: Balancing immune responses – multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

BackgroundCombination treatment with BRAF/MEK inhibitors favorably impact progression-free survival in malignant melanoma. However, it may cause paradoxical activation of the MAPK/ERK pathway in immune cells without BRAF mutation, which may lead to over activation of the immune system, especially in...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Katrin Pape, Maria Protopapa, Muriel Schraad, Falk Steffen, Frauke Zipp, Stefan Bittner
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-11-01
Serie:	Frontiers in Oncology
Soggetti:	malignant melanoma BRAF/MEK treatment multiple sclerosis B cell depletion ocrelizumab multi-color flow cytometry
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1303141/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!